AU2018260666B2 - Methods and compositions for treating sleep apnea - Google Patents
Methods and compositions for treating sleep apnea Download PDFInfo
- Publication number
- AU2018260666B2 AU2018260666B2 AU2018260666A AU2018260666A AU2018260666B2 AU 2018260666 B2 AU2018260666 B2 AU 2018260666B2 AU 2018260666 A AU2018260666 A AU 2018260666A AU 2018260666 A AU2018260666 A AU 2018260666A AU 2018260666 B2 AU2018260666 B2 AU 2018260666B2
- Authority
- AU
- Australia
- Prior art keywords
- atomoxetine
- oxybutynin
- receptor antagonist
- nri
- muscarinic receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022241471A AU2022241471A1 (en) | 2017-04-28 | 2022-09-27 | Methods and compositions for treating sleep apnea |
| AU2025230729A AU2025230729A1 (en) | 2017-04-28 | 2025-09-11 | Methods and compositions for treating sleep apnea |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491504P | 2017-04-28 | 2017-04-28 | |
| US62/491,504 | 2017-04-28 | ||
| US201762558814P | 2017-09-14 | 2017-09-14 | |
| US62/558,814 | 2017-09-14 | ||
| PCT/US2018/029518 WO2018200775A1 (en) | 2017-04-28 | 2018-04-26 | Methods and compositions for treating sleep apnea |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022241471A Division AU2022241471A1 (en) | 2017-04-28 | 2022-09-27 | Methods and compositions for treating sleep apnea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018260666A1 AU2018260666A1 (en) | 2019-11-14 |
| AU2018260666B2 true AU2018260666B2 (en) | 2022-07-21 |
Family
ID=63918622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018260666A Active AU2018260666B2 (en) | 2017-04-28 | 2018-04-26 | Methods and compositions for treating sleep apnea |
| AU2022241471A Abandoned AU2022241471A1 (en) | 2017-04-28 | 2022-09-27 | Methods and compositions for treating sleep apnea |
| AU2025230729A Pending AU2025230729A1 (en) | 2017-04-28 | 2025-09-11 | Methods and compositions for treating sleep apnea |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022241471A Abandoned AU2022241471A1 (en) | 2017-04-28 | 2022-09-27 | Methods and compositions for treating sleep apnea |
| AU2025230729A Pending AU2025230729A1 (en) | 2017-04-28 | 2025-09-11 | Methods and compositions for treating sleep apnea |
Country Status (21)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119185558A (zh) * | 2017-04-28 | 2024-12-27 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CN111670050A (zh) | 2018-01-30 | 2020-09-15 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CN108309261B (zh) * | 2018-02-11 | 2020-05-22 | 西安交通大学 | 一种猝死预警方法及装置和系统 |
| WO2019245975A1 (en) | 2018-06-17 | 2019-12-26 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| CA3117766A1 (en) * | 2018-10-31 | 2020-05-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| ES3049086T3 (en) * | 2019-02-08 | 2025-12-12 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| US12616702B2 (en) | 2019-12-03 | 2026-05-05 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| EP4146621A1 (en) | 2020-05-05 | 2023-03-15 | Apnimed, Inc. (Delaware) | Polymorphic forms of (r)-oxybutynin hydrochloride |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| RU2757470C1 (ru) * | 2020-11-19 | 2021-10-18 | Ренат Рашитович Ахмеров | Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы |
| US20240075035A1 (en) * | 2021-01-14 | 2024-03-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CA3210092A1 (en) * | 2021-03-04 | 2022-09-09 | Lawrence G. Miller | Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea |
| CN117177741A (zh) * | 2021-04-16 | 2023-12-05 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合 |
| JP2024523876A (ja) * | 2021-06-17 | 2024-07-02 | アプニメッド,インコーポレイテッド(デラウェア) | 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤 |
| JP2024534173A (ja) * | 2021-08-31 | 2024-09-18 | アプニメッド,インコーポレイテッド(デラウェア) | 睡眠時無呼吸を治療するための方法及び組成物 |
| CA3259602A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea |
| MX2024007768A (es) | 2021-12-22 | 2024-07-01 | Bayer Ag | Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o. |
| IL313648A (en) * | 2021-12-22 | 2024-08-01 | Bayer Ag | Combination of a TASK1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| EP4522149A1 (en) * | 2022-05-13 | 2025-03-19 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| US20260041659A1 (en) * | 2024-08-07 | 2026-02-12 | Yogesh Dandiker | Topical atomoxetine and oxybutynin for obstructive sleep apnea |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020010216A1 (en) * | 2000-02-24 | 2002-01-24 | Karen Rogosky | New drug combinations |
| US20060039867A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders with setiptiline |
| WO2006069030A1 (en) * | 2004-12-20 | 2006-06-29 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| AU767877B2 (en) | 1999-05-20 | 2003-11-27 | Sepracor, Inc. | Methods for treatment of asthma using S-oxybutynin |
| CN107007602A (zh) * | 2011-01-28 | 2017-08-04 | 辉达斯医学研究所 | 治疗阻塞性睡眠呼吸暂停的方法 |
| CN119185558A (zh) * | 2017-04-28 | 2024-12-27 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CN111670050A (zh) | 2018-01-30 | 2020-09-15 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
-
2018
- 2018-04-26 CN CN202411366994.9A patent/CN119185558A/zh active Pending
- 2018-04-26 MA MA049069A patent/MA49069A/fr unknown
- 2018-04-26 GE GEAP202416602A patent/GEAP202416602A/en unknown
- 2018-04-26 US US16/609,048 patent/US11123313B2/en active Active
- 2018-04-26 GE GEAP201816320A patent/GEP20257788B/en unknown
- 2018-04-26 UA UAA201910615A patent/UA127759C2/uk unknown
- 2018-04-26 AU AU2018260666A patent/AU2018260666B2/en active Active
- 2018-04-26 CR CR20190546A patent/CR20190546A/es unknown
- 2018-04-26 KR KR1020257032249A patent/KR20250145704A/ko active Pending
- 2018-04-26 MX MX2019012729A patent/MX394941B/es unknown
- 2018-04-26 JP JP2019558554A patent/JP7373997B2/ja active Active
- 2018-04-26 KR KR1020197034523A patent/KR102682159B1/ko active Active
- 2018-04-26 GE GEAP202316320A patent/GEAP202316320A/en unknown
- 2018-04-26 SG SG11201909973U patent/SG11201909973UA/en unknown
- 2018-04-26 CA CA3061468A patent/CA3061468A1/en active Pending
- 2018-04-26 SG SG10202111623TA patent/SG10202111623TA/en unknown
- 2018-04-26 GE GEAP202115226A patent/GEAP202115226A/en unknown
- 2018-04-26 WO PCT/US2018/029518 patent/WO2018200775A1/en not_active Ceased
- 2018-04-26 MY MYPI2019006319A patent/MY200172A/en unknown
- 2018-04-26 GE GEAP201815757A patent/GEP20247617B/en unknown
- 2018-04-26 CN CN201880042623.1A patent/CN110799181A/zh active Pending
- 2018-04-26 GE GEAP201815226A patent/GEP20227387B/en unknown
- 2018-04-26 KR KR1020247009759A patent/KR20240042261A/ko not_active Ceased
- 2018-04-26 EP EP18791670.5A patent/EP3615016A4/en active Pending
-
2019
- 2019-10-24 MX MX2022010349A patent/MX2022010349A/es unknown
- 2019-10-25 DO DO2019000274A patent/DOP2019000274A/es unknown
- 2019-10-25 NI NI201900110A patent/NI201900110A/es unknown
- 2019-10-25 PH PH12019502427A patent/PH12019502427A1/en unknown
- 2019-10-29 ZA ZA2019/07158A patent/ZA201907158B/en unknown
- 2019-11-25 EC ECSENADI201984058A patent/ECSP19084058A/es unknown
- 2019-11-26 CO CONC2019/0013180A patent/CO2019013180A2/es unknown
-
2021
- 2021-09-10 US US17/471,892 patent/US20210401777A1/en not_active Abandoned
-
2022
- 2022-09-27 AU AU2022241471A patent/AU2022241471A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108387A patent/JP2023139000A/ja active Pending
- 2023-07-19 US US18/355,178 patent/US20240189261A1/en not_active Abandoned
-
2024
- 2024-03-04 US US18/594,885 patent/US20240261239A1/en not_active Abandoned
-
2025
- 2025-07-10 US US19/265,336 patent/US20260007618A1/en active Pending
- 2025-07-31 JP JP2025128090A patent/JP2025169279A/ja active Pending
- 2025-09-11 AU AU2025230729A patent/AU2025230729A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020010216A1 (en) * | 2000-02-24 | 2002-01-24 | Karen Rogosky | New drug combinations |
| US20060039867A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders with setiptiline |
| WO2006069030A1 (en) * | 2004-12-20 | 2006-06-29 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
Non-Patent Citations (2)
| Title |
|---|
| BART SANGAL R ET AL: "Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness", SLEEP MEDICINE, vol. 9, no. 5, 2008, pg 506 * |
| TARANTO-MONTEMURRO ET AL., Desipramine Increases Genioglossus Activity and Reduces Upper Airway Collapsibility during Non-REM Sleep in Healthy Subjects, AM. J OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 194, no. 7, 2016, pages 878 - 885 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240189261A1 (en) | Methods and compositions for treating sleep apnea | |
| US20250186371A1 (en) | Methods and compositions for treating sleep apnea | |
| OA19434A (en) | Methods and compositions for treating sleep apnea. | |
| HK40117857A (en) | Methods and compositions for treating sleep apnea | |
| HK40120547A (en) | Methods and compositions for treating sleep apnea | |
| EA045789B1 (ru) | Способы и композиции для лечения апноэ во сне | |
| BR112019022483B1 (pt) | Composição farmacêutica e kit compreendendo um inibidor de reabsorção de norepinefrina e um antagonista de receptor muscarínico e seus usos | |
| HK40013951A (en) | Methods and compositions for treating sleep apnea | |
| EA047115B1 (ru) | Способы и композиции для лечения апноэ сна |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |